Frederick Pierce

GlycoGenesys, Inc., a biotechnology company, develops novel pharmaceutical products based on carbohydrate compounds and related technologies. The company's lead drug candidate GCS-100, a treatment for various forms of solid tumors and bloodborne cancers, completed a Phase II (a) clinical trial for pancreatic cancer, and also completed a Phase II (a) clinical trial for colorectal cancer. The company focuses on the development of carbohydrate-based pharmaceutical products and related technologies in connection with oncology. It was founded in 1992 and is headquartered in Boston, MA.

Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA.

SanaRx Biotherapeutics, Inc. is a biotechnology company. It serves patients with orphan diseases of the alimentary tract. The company is headquartered in Medford, MA.

SemBioSys Genetics, Inc. operates as a plant-based technology development company, which engages in the manufacturing technology platforms to develop, manufacture and commercialize healthy living, animal health and pharmaceutical products. It offers proteins, functional food and nutritional products. The company was founded by Maurice Moloney on April 25, 1994 and is headquartered in Calgary, Canada.

Canadian Entrepreneurs In New England operates a membership organization that supports Canadian technology and life sciences entrepreneurs. The private company is based in Boston. The American company was founded by Chris Legg.